Safety and efficacy of p38 mitogen-activated protein kinase inhibitors (MAPKIs) in COPD
Introduction: Chronic inflammation is the core mechanism of the development of chronic obstructive pulmonary disease (COPD). Corticosteroid resistance in COPD limits its anti-inflammatory potency. p38 MAPKIs were suggested as an alternative to corticosteroids despite the fact that there is currently...
Main Authors: | Haichuan Yu, Xiaojie Su, Ting Lei, Lu Zhang, Zhouzhou Feng, Chuchu Zhang, Meng Zhang, Yalei Wang, Xinlong Chen, Jian Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.950035/full |
Similar Items
-
A systematic review and Bayesian meta-analysis of the antibiotic treatment courses in AECOPD
by: Haichuan Yu, et al.
Published: (2023-01-01) -
Efficacy and safety of three species of Rhodiola L. in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
by: Haichuan Yu, et al.
Published: (2023-04-01) -
Discoidin domain receptor 2 activation of p38 mitogen-activated protein kinase as an important pathway for osteonectin-regulating osteoblast mineralization
by: Yun-Sen Zhu, et al.
Published: (2021-12-01) -
Design, synthesis, and study of novel phenethyl-based antitumor phospholipids downregulating p38 mitogen-activated protein kinase
by: Ahmed H. E. Hassan, et al.
Published: (2023-12-01) -
p38β and Cancer: The Beginning of the Road
by: Olga Roche, et al.
Published: (2020-10-01)